Positron（POSC）株式概要ポジトロン・コーポレーションは核医学ヘルスケア企業で、米国では心臓ポジトロン断層撮影（PET）イメージング事業を専門としている。 詳細POSC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析過去1年間で収益は18.2%減少しました キャッシュランウェイが1年未満である 収益が 100 万ドル未満 ( $453K )意味のある時価総額がありません ( $61M )すべてのリスクチェックを見るPOSC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.856.8k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-10m1m2016201920222025202620282031Revenue US$453.1kEarnings US$61.5kAdvancedSet Fair ValueView all narrativesPositron Corporation 競合他社DaxorSymbol: NasdaqCM:DXRMarket cap: US$63.1mQT Imaging HoldingsSymbol: NasdaqCM:QTIMarket cap: US$66.6mLENSARSymbol: NasdaqCM:LNSRMarket cap: US$73.7mOutset MedicalSymbol: NasdaqGS:OMMarket cap: US$80.1m価格と性能株価の高値、安値、推移の概要Positron過去の株価現在の株価US$1.8552週高値US$2.7452週安値US$1.25ベータ0.151ヶ月の変化1.09%3ヶ月変化-20.26%1年変化17.09%3年間の変化36.78%5年間の変化198.39%IPOからの変化-99.90%最新ニュースお知らせ • May 29Positron Corporation Expands Market Presence with Sale of NeuSight Pet-CT ScannerPositron Corporation announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron's PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, technical and training support. Positron continues to deliver the most effective and cost-efficient imaging platform for nuclear cardiology and molecular imaging practices nationwide. The NeuSight PET- CT is engineered to elevate cardiac PET imaging through a unique combination of advanced technology, exceptional performance, and unmatched value. Internationally recognized, the system features a spacious 72 cm gantry for patient comfort and high-sensitivity acquisition that reduces radiation exposure for both patients and staff. With the smallest footprint and lightest weight in its class, NeuSight is ideal for all healthcare environments where space and efficiency matter. Offering both anatomic and functional imaging, it supports a wide range of studies--including cardiac, tumor, and neurological imaging -- making it a powerful tool for practices committed to delivering superior patient care.お知らせ • Jan 29Positron Corporation Announces Sales of Attrius Pet and Neusight Pet-Ct 64 Slice Nuclear Imaging SystemsPositron Corporation announced sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices. The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve. The NeuSight PET-ct is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET- CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities. As a cost-effective and innovative system, the NeuSightPET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight Pet-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.お知らせ • Jul 25Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CTPositron Corporation announced to present its new NeuSight PET-CT 3D 64 slice scanner, available for US and North American Markets. The NeuSightPET-CT advanced technology sets a new standard in imaging and diagnostic precision, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals. The NeuSight PET-CT was designed to revolutionize cardiac PET imaging, offering unparalleled value, empowering practices with cutting-edge technology at an unmatched price. The NeuSight PET-CT scanner is a highly acclaimed, top performing scanner, with installations throughout the world. The NeuSight PET-CT is an innovative, inexpensive PET-CT system making it ideal for both cardiology and oncology clinical studies having superior data acquisition, with identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology, serving multiple molecular imaging functions for heart, tumor, and brain imaging studies. NeuSight PET-CT’s detector modules are designed to interface with scintillating crystals for improved photoelectric conversion efficiency, high sensitivity, and temporal resolution. Proprietary IPIE technology improves spatial resolution and data accuracy. A key feature of NeuSight PET-CT incorporates clear honeycomb and patented asymmetrical light-guided technology delivering superior image clarity and resolution, essential for accurate cardiac diagnostics. Advanced clinical applications from 4D Gate capabilities for precise attenuation correction and fusion to optimized image fusion algorithms and quality control procedures, the system enables clinicians to achieve superior clinical outcomes with every scan.お知らせ • Dec 21Positron Corporation Announces Plans for Clinical Study of Its New “Affinity Pet-Ct 4D” Nuclear Imaging DevicePositron Corporation announced the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” nuclear imaging device. The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health. Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations. Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP). Following the formalization of the plan with IRB and on-site installation the clinical study is expected to begin in mid-January with an estimated time of completion of three (3) weeks. The study will be performed at Ochsner Health’s New Orleans facility under the guidance of Dr. Bober. The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with cardiac PET imaging agents. Testing will encompass an extensive array of patients, comprising of a diverse range of ages, body habitus, and clinical indications. The results of the study and data received will be organized by Dr. Bober and disseminated as collateral for Positron’s Affinity PET-CT 4D marketing efforts.最新情報をもっと見るRecent updatesお知らせ • May 29Positron Corporation Expands Market Presence with Sale of NeuSight Pet-CT ScannerPositron Corporation announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron's PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, technical and training support. Positron continues to deliver the most effective and cost-efficient imaging platform for nuclear cardiology and molecular imaging practices nationwide. The NeuSight PET- CT is engineered to elevate cardiac PET imaging through a unique combination of advanced technology, exceptional performance, and unmatched value. Internationally recognized, the system features a spacious 72 cm gantry for patient comfort and high-sensitivity acquisition that reduces radiation exposure for both patients and staff. With the smallest footprint and lightest weight in its class, NeuSight is ideal for all healthcare environments where space and efficiency matter. Offering both anatomic and functional imaging, it supports a wide range of studies--including cardiac, tumor, and neurological imaging -- making it a powerful tool for practices committed to delivering superior patient care.お知らせ • Jan 29Positron Corporation Announces Sales of Attrius Pet and Neusight Pet-Ct 64 Slice Nuclear Imaging SystemsPositron Corporation announced sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices. The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve. The NeuSight PET-ct is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET- CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities. As a cost-effective and innovative system, the NeuSightPET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight Pet-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.お知らせ • Jul 25Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CTPositron Corporation announced to present its new NeuSight PET-CT 3D 64 slice scanner, available for US and North American Markets. The NeuSightPET-CT advanced technology sets a new standard in imaging and diagnostic precision, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals. The NeuSight PET-CT was designed to revolutionize cardiac PET imaging, offering unparalleled value, empowering practices with cutting-edge technology at an unmatched price. The NeuSight PET-CT scanner is a highly acclaimed, top performing scanner, with installations throughout the world. The NeuSight PET-CT is an innovative, inexpensive PET-CT system making it ideal for both cardiology and oncology clinical studies having superior data acquisition, with identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology, serving multiple molecular imaging functions for heart, tumor, and brain imaging studies. NeuSight PET-CT’s detector modules are designed to interface with scintillating crystals for improved photoelectric conversion efficiency, high sensitivity, and temporal resolution. Proprietary IPIE technology improves spatial resolution and data accuracy. A key feature of NeuSight PET-CT incorporates clear honeycomb and patented asymmetrical light-guided technology delivering superior image clarity and resolution, essential for accurate cardiac diagnostics. Advanced clinical applications from 4D Gate capabilities for precise attenuation correction and fusion to optimized image fusion algorithms and quality control procedures, the system enables clinicians to achieve superior clinical outcomes with every scan.お知らせ • Dec 21Positron Corporation Announces Plans for Clinical Study of Its New “Affinity Pet-Ct 4D” Nuclear Imaging DevicePositron Corporation announced the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” nuclear imaging device. The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health. Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations. Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP). Following the formalization of the plan with IRB and on-site installation the clinical study is expected to begin in mid-January with an estimated time of completion of three (3) weeks. The study will be performed at Ochsner Health’s New Orleans facility under the guidance of Dr. Bober. The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with cardiac PET imaging agents. Testing will encompass an extensive array of patients, comprising of a diverse range of ages, body habitus, and clinical indications. The results of the study and data received will be organized by Dr. Bober and disseminated as collateral for Positron’s Affinity PET-CT 4D marketing efforts.株主還元POSCUS Medical EquipmentUS 市場7D-4.9%4.4%1.0%1Y17.1%-17.9%28.7%株主還元を見る業界別リターン: POSC過去 1 年間で-17.9 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: POSCは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is POSC's price volatile compared to industry and market?POSC volatilityPOSC Average Weekly Movement10.5%Medical Equipment Industry Average Movement8.7%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: POSC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: POSCの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト198310n/awww.positron.com核医学ヘルスケア企業であるPositron Corporationは、米国で心臓陽電子放射断層撮影（PET）イメージング事業を専門としている。アトリウスPETスキャナー、臨床・技術サービス、資金調達ソリューションを提供し、医療従事者が心臓疾患を正確に診断し、患者の転帰を改善し、費用対効果の高い医薬品を実践できるようにしている。ポジトロン・コーポレーションは1983年に設立され、ニューヨーク州ナイアガラフォールズに本社を置いている。もっと見るPositron Corporation 基礎のまとめPositron の収益と売上を時価総額と比較するとどうか。POSC 基礎統計学時価総額US$60.77m収益（TTM）-US$10.47m売上高(TTM)US$453.12k134.1xP/Sレシオ-5.8xPER（株価収益率POSC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計POSC 損益計算書（TTM）収益US$453.12k売上原価US$2.84m売上総利益-US$2.38mその他の費用US$8.09m収益-US$10.47m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.32グロス・マージン-526.00%純利益率-2,310.38%有利子負債／自己資本比率545.0%POSC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 02:41終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Positron Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 29Positron Corporation Expands Market Presence with Sale of NeuSight Pet-CT ScannerPositron Corporation announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron's PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, technical and training support. Positron continues to deliver the most effective and cost-efficient imaging platform for nuclear cardiology and molecular imaging practices nationwide. The NeuSight PET- CT is engineered to elevate cardiac PET imaging through a unique combination of advanced technology, exceptional performance, and unmatched value. Internationally recognized, the system features a spacious 72 cm gantry for patient comfort and high-sensitivity acquisition that reduces radiation exposure for both patients and staff. With the smallest footprint and lightest weight in its class, NeuSight is ideal for all healthcare environments where space and efficiency matter. Offering both anatomic and functional imaging, it supports a wide range of studies--including cardiac, tumor, and neurological imaging -- making it a powerful tool for practices committed to delivering superior patient care.
お知らせ • Jan 29Positron Corporation Announces Sales of Attrius Pet and Neusight Pet-Ct 64 Slice Nuclear Imaging SystemsPositron Corporation announced sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices. The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve. The NeuSight PET-ct is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET- CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities. As a cost-effective and innovative system, the NeuSightPET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight Pet-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.
お知らせ • Jul 25Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CTPositron Corporation announced to present its new NeuSight PET-CT 3D 64 slice scanner, available for US and North American Markets. The NeuSightPET-CT advanced technology sets a new standard in imaging and diagnostic precision, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals. The NeuSight PET-CT was designed to revolutionize cardiac PET imaging, offering unparalleled value, empowering practices with cutting-edge technology at an unmatched price. The NeuSight PET-CT scanner is a highly acclaimed, top performing scanner, with installations throughout the world. The NeuSight PET-CT is an innovative, inexpensive PET-CT system making it ideal for both cardiology and oncology clinical studies having superior data acquisition, with identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology, serving multiple molecular imaging functions for heart, tumor, and brain imaging studies. NeuSight PET-CT’s detector modules are designed to interface with scintillating crystals for improved photoelectric conversion efficiency, high sensitivity, and temporal resolution. Proprietary IPIE technology improves spatial resolution and data accuracy. A key feature of NeuSight PET-CT incorporates clear honeycomb and patented asymmetrical light-guided technology delivering superior image clarity and resolution, essential for accurate cardiac diagnostics. Advanced clinical applications from 4D Gate capabilities for precise attenuation correction and fusion to optimized image fusion algorithms and quality control procedures, the system enables clinicians to achieve superior clinical outcomes with every scan.
お知らせ • Dec 21Positron Corporation Announces Plans for Clinical Study of Its New “Affinity Pet-Ct 4D” Nuclear Imaging DevicePositron Corporation announced the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” nuclear imaging device. The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health. Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations. Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP). Following the formalization of the plan with IRB and on-site installation the clinical study is expected to begin in mid-January with an estimated time of completion of three (3) weeks. The study will be performed at Ochsner Health’s New Orleans facility under the guidance of Dr. Bober. The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with cardiac PET imaging agents. Testing will encompass an extensive array of patients, comprising of a diverse range of ages, body habitus, and clinical indications. The results of the study and data received will be organized by Dr. Bober and disseminated as collateral for Positron’s Affinity PET-CT 4D marketing efforts.
お知らせ • May 29Positron Corporation Expands Market Presence with Sale of NeuSight Pet-CT ScannerPositron Corporation announced the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron's PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, technical and training support. Positron continues to deliver the most effective and cost-efficient imaging platform for nuclear cardiology and molecular imaging practices nationwide. The NeuSight PET- CT is engineered to elevate cardiac PET imaging through a unique combination of advanced technology, exceptional performance, and unmatched value. Internationally recognized, the system features a spacious 72 cm gantry for patient comfort and high-sensitivity acquisition that reduces radiation exposure for both patients and staff. With the smallest footprint and lightest weight in its class, NeuSight is ideal for all healthcare environments where space and efficiency matter. Offering both anatomic and functional imaging, it supports a wide range of studies--including cardiac, tumor, and neurological imaging -- making it a powerful tool for practices committed to delivering superior patient care.
お知らせ • Jan 29Positron Corporation Announces Sales of Attrius Pet and Neusight Pet-Ct 64 Slice Nuclear Imaging SystemsPositron Corporation announced sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices. The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve. The NeuSight PET-ct is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET- CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities. As a cost-effective and innovative system, the NeuSightPET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight Pet-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.
お知らせ • Jul 25Positron Corporation Introduces New, Advanced Designed, Economically Priced PET-CTPositron Corporation announced to present its new NeuSight PET-CT 3D 64 slice scanner, available for US and North American Markets. The NeuSightPET-CT advanced technology sets a new standard in imaging and diagnostic precision, patient comfort, and operational efficiency for nuclear cardiology practices and hospitals. The NeuSight PET-CT was designed to revolutionize cardiac PET imaging, offering unparalleled value, empowering practices with cutting-edge technology at an unmatched price. The NeuSight PET-CT scanner is a highly acclaimed, top performing scanner, with installations throughout the world. The NeuSight PET-CT is an innovative, inexpensive PET-CT system making it ideal for both cardiology and oncology clinical studies having superior data acquisition, with identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology, serving multiple molecular imaging functions for heart, tumor, and brain imaging studies. NeuSight PET-CT’s detector modules are designed to interface with scintillating crystals for improved photoelectric conversion efficiency, high sensitivity, and temporal resolution. Proprietary IPIE technology improves spatial resolution and data accuracy. A key feature of NeuSight PET-CT incorporates clear honeycomb and patented asymmetrical light-guided technology delivering superior image clarity and resolution, essential for accurate cardiac diagnostics. Advanced clinical applications from 4D Gate capabilities for precise attenuation correction and fusion to optimized image fusion algorithms and quality control procedures, the system enables clinicians to achieve superior clinical outcomes with every scan.
お知らせ • Dec 21Positron Corporation Announces Plans for Clinical Study of Its New “Affinity Pet-Ct 4D” Nuclear Imaging DevicePositron Corporation announced the Company’s collaboration with Dr. Bober and Ochsner Health, the largest non-profit, academic healthcare system operating in Louisiana, for the clinical study of Positron’s new “Affinity PET-CT 4D” nuclear imaging device. The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health. Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations. Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP). Following the formalization of the plan with IRB and on-site installation the clinical study is expected to begin in mid-January with an estimated time of completion of three (3) weeks. The study will be performed at Ochsner Health’s New Orleans facility under the guidance of Dr. Bober. The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with cardiac PET imaging agents. Testing will encompass an extensive array of patients, comprising of a diverse range of ages, body habitus, and clinical indications. The results of the study and data received will be organized by Dr. Bober and disseminated as collateral for Positron’s Affinity PET-CT 4D marketing efforts.
